
0:00
1:26:37
In this episode of Lung Cancer Considered, Drs. Jacob Sands, Ferdinandos Skoulidis, and Jarushka Naidoo discuss key research highlights from ESMO 2026, including results from the DeLLphi-305 trial evaluating tarlatamab in extensive-stage small cell lung cancer and the KRAScendo-1 trial investigating divarasib in KRAS G12C-mutated NSCLC. The discussion also explores emerging immunotherapy strategies, including findings from the MOIO and OptiTROP-Lung06 studies, advances in predicting immune-related toxicities, and the potential implications of these developments for clinical practice.
Jaruska Naidoo, MD
Professor of Medical Oncology
Royal College of Surgeons
Consultant, Medical Oncologist at Beaumont Hospital
X: @DrJNaidoo
Instagram: jarushkanaidoo
LinkedIn: https://www.linkedin.com/in/jarushka-naidoo-127a3b97/
Jacob Sands, MD
Assistant Professor of Medicine, Harvard Medical School
Associate Chief, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
X: @sands_jacob
Instagram: jacobsands
LinkedIn: https://www.linkedin.com/in/jacobsands/
Ferdinandos Skoulidis, MD, PhD
Professor, Department of Thoracic and Head and Neck Medical Oncology
University of Texas MD Anderson Cancer Center
More episodes from "Lung Cancer Considered"



Don't miss an episode of “Lung Cancer Considered” and subscribe to it in the GetPodcast app.








